{
    "nctId": "NCT01225172",
    "briefTitle": "Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors",
    "officialTitle": "A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 77,
    "primaryOutcomeMeasure": "Progression Free Survival Rate at 24 Weeks",
    "eligibilityCriteria": "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n\n* Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer\n* Disease progression following non-steroidal aromatase inhibitor treatment\n\nExclusion Criteria:\n\n* Known symptomatic brain metastasis\n* Medical condition requiring chronic steroids\n* History of Type 1 or 2 Diabetes\n* Uncontrolled or significant cardiovascular (CV) disease\n* Concomitant second malignancies",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}